ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
Version 3 2024-06-20, 01:19
Version 2 2024-05-30, 15:26
Version 1 2014-10-28, 09:59
journal contribution
posted on 2024-06-20, 01:19 authored by Ajeet SinghAjeet Singh, CA Bousman, CH Ng, K Byron, Michael BerkMichael BerkABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
History
Journal
Translational PsychiatryVolume
2Article number
ARTN e198Pagination
1 - 6Location
United StatesPublisher DOI
Open access
- Yes
ISSN
2158-3188eISSN
2158-3188Language
EnglishPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2012, Macmillan Publishers LimitedIssue
11Publisher
NATURE PUBLISHING GROUPPublication URL
Usage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicinePsychiatryABCB1pharmacogeneticsantidepressantmajor depressionblood-brain barrierP-glycoproteinBLOOD-BRAIN-BARRIERP-GLYCOPROTEIN GENEMULTIDRUG-RESISTANCE GENELINKAGE DISEQUILIBRIUMDRUG-PERMEABILITYMDR1PENETRATIONMICEHAPLOTYPESC3435T110399 Clinical Sciences not elsewhere classified970111 Expanding Knowledge in the Medical and Health Sciences
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC